Hemodialysis-resistant hypertension: control with an orally active inhibitor of angiotensin-converting enzyme.
作者信息
Vaughan E D, Carey R M, Ayers C R, Peach M J
出版信息
J Clin Endocrinol Metab. 1979 May;48(5):869-71. doi: 10.1210/jcem-48-5-869.
PMID:219011
Abstract
In two patients with end stage renal disease and dialysis-resistant hypertension, the orally active inhibitor of angiotensin-converting enzyme, captopril (SQ14,225; 2-D-methyl-3-mercaptopropranoyl-L-proline, dramatically lowered blood pressure both before and during dialysis. This agent holds promise as an alternate to bilateral nephrectomy in such patients.
摘要
Zotero 插件